Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02262845 · ClinicalTrials.gov registry record
Short Term Pancreatic Stenting Registry
A clinical trial of Post-ERCP Acute Pancreatitis and Pancreatic Duct Stricture, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 246
- Enrollment target
- 7
- Study locations
NCT02262845: Completed study of Post-ERCP Acute Pancreatitis and Pancreatic Duct Stricture, sponsored by Boston Scientific Corporation.
NCT02262845 is a study of Post-ERCP Acute Pancreatitis and Pancreatic Duct Stricture that has completed, run by Boston Scientific Corporation. The registered enrollment target is 246 participants. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02262845, a study of Post-ERCP Acute Pancreatitis and Pancreatic Duct Stricture, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 246 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to document clinical utility and distribution of indications for short term pancreatic stenting, and stent type preference by indication at tertiary referral centers with expertise in pancreatic endotherapy.
Primary Outcome
Absence of acute pancreatitis from stent placement through 48 hours post stent placement
Conditions Studied
Interventions
- DEVICE The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
Study Locations (7)
Other
- Evangelisches Krankenhaus Dusseldorf - Düsseldorf
- Erasmus Medical Center - Rotterdam
Pennsylvania
- Temple University School of Medicine - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Texas
- Methodist Dallas Medical Center - Dallas
Washington
- Virginia Mason Medical Center - Seattle
Hyderabad
- Asian Institute of Gastroenterology - Somājigūda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-09 |
What the finished NCT02262845 record still lists
NCT02262845 is an observational study that tracks outcomes without assigning an intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap.
The record links to 4 conditions, with Post-ERCP Acute Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers is the first listed.
NCT02262845 lists 7 locations in 6 states (Other, Pennsylvania, South Carolina).
Frequently Asked Questions
What is clinical trial NCT02262845 about?
NCT02262845 is a clinical study titled "Short Term Pancreatic Stenting Registry". The purpose of this study is to document clinical utility and distribution of indications for short term pancreatic stenting, and stent type preference by indication at tertiary referral centers with expertise in pancreatic endotherapy.
What is the current status of trial NCT02262845?
This trial is currently completed. The enrollment target is 246 participants. The study started on 2015-02. Estimated completion is 2016-09.
What conditions does trial NCT02262845 study?
This clinical trial studies the following conditions: Post-ERCP Acute Pancreatitis, Pancreatic Duct Stricture, Pancreatic Duct Stones, Pancreatic Duct Leakage.
What interventions are being tested in trial NCT02262845?
The interventions under investigation include: The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers (DEVICE).
Who is sponsoring clinical trial NCT02262845?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02262845 being conducted?
This trial has 7 study locations across Pennsylvania, South Carolina, Texas, Washington, Hyderabad. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-ERCP Acute Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia